Watson's Opana ANDA Triggers Endo, Penwest Suit

By Ben James

Law360, New York (March 09, 2010, 3:32 PM ET) -- Watson Pharmaceuticals Inc. has revealed that it is facing a patent infringement suit from Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. following the generics maker's bid for approval of its own version of painkiller Opana ER.

Watson announced Monday that subsidiary Watson Laboratories Inc. had been sued by Endo and Penwest in connection with an abbreviated new drug application asking the U.S. Food and Drug Administration to approve 40 mg oxymorphone hydrochloride extended release tablets, a generic version of Opana.

In January, Watson alerted Endo and...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles